Tasly Pharmaceutical Group Co., Ltd

$ 14.09 -0.07 %

Tasly Pharmaceutical Group Co., Ltd., a company founded in 1994 and based in Tianjin, China, is actively engaged in the biological medicine, health, and medical service industries within China. Its extensive product catalog encompasses a wide range of goods, including both traditional herbal and modern chemical medicines, alongside various health supplements. The firm also supplies key pharmaceutical ingredients (APIs), concentrated herbal granules, herbal extracts, and a diverse selection of tea products. Beyond its core pharmaceutical offerings, Tasly manufactures cosmetic lines featuring items such as moisturizing lotions, facial creams, eye creams, and cleansing foams. Additionally, its consumer goods division provides daily hygiene essentials like sanitary and carefree pads, in addition to specialized soaps made with honey-propolis and pollen. The company further distributes medical equipment, including different types of massage devices like tappers and cushions, as well as circulation-enhancing machines. Tasly's market presence extends globally, with significant exports directed to the United States, Russia, and numerous countries across Europe, Africa, and other parts of Asia.

CEO: Jin Yong Cai - https://www.tasly.com

Price objectif

-

Recommandation

-

DCF

$ 29.65

Loading data...

600535.SS vs S&P500

Loading data...

No data available.

Quick ratio

3.09

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

18.06

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.78

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

9.32 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

7.60 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.58

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.10

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.35

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

28.18 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
6.64 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.27 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.08 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.